GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Petros Pharmaceuticals Inc (NAS:PTPI) » Definitions » PS Ratio

Petros Pharmaceuticals (Petros Pharmaceuticals) PS Ratio : 0.23 (As of May. 12, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Petros Pharmaceuticals PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Petros Pharmaceuticals's share price is $0.63837. Petros Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $2.78. Hence, Petros Pharmaceuticals's PS Ratio for today is 0.23.

Good Sign:

Petros Pharmaceuticals Inc stock PS Ratio (=0.24) is close to 5-year low of 0.23

The historical rank and industry rank for Petros Pharmaceuticals's PS Ratio or its related term are showing as below:

PTPI' s PS Ratio Range Over the Past 10 Years
Min: 0.23   Med: 1.63   Max: 6.44
Current: 0.23

During the past 5 years, Petros Pharmaceuticals's highest PS Ratio was 6.44. The lowest was 0.23. And the median was 1.63.

PTPI's PS Ratio is ranked better than
94.72% of 1004 companies
in the Drug Manufacturers industry
Industry Median: 2.21 vs PTPI: 0.23

Petros Pharmaceuticals's Revenue per Sharefor the three months ended in Dec. 2023 was $-0.15. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $2.78.

Warning Sign:

Petros Pharmaceuticals Inc revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue per Share Growth Rate of Petros Pharmaceuticals was -7.60% per year. During the past 3 years, the average Revenue per Share Growth Rate was -46.90% per year.

During the past 5 years, Petros Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was -43.50% per year. The lowest was -46.90% per year. And the median was -45.20% per year.

Back to Basics: PS Ratio


Petros Pharmaceuticals PS Ratio Historical Data

The historical data trend for Petros Pharmaceuticals's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Petros Pharmaceuticals PS Ratio Chart

Petros Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
- 2.46 4.64 0.80 0.53

Petros Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.80 0.48 1.11 0.52 0.53

Competitive Comparison of Petros Pharmaceuticals's PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Petros Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Petros Pharmaceuticals's PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Petros Pharmaceuticals's PS Ratio distribution charts can be found below:

* The bar in red indicates where Petros Pharmaceuticals's PS Ratio falls into.



Petros Pharmaceuticals PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Petros Pharmaceuticals's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.63837/2.783
=0.23

Petros Pharmaceuticals's Share Price of today is $0.63837.
Petros Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.78.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Petros Pharmaceuticals  (NAS:PTPI) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Petros Pharmaceuticals PS Ratio Related Terms

Thank you for viewing the detailed overview of Petros Pharmaceuticals's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Petros Pharmaceuticals (Petros Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1185 Avenue of the Americas, 3rd Floor, New York, NY, USA, 10036
Petros Pharmaceuticals Inc is a men's health pharmaceutical company. It focuses on identifying, developing, acquiring, and commercializing innovative therapeutics for men's health issues including erectile dysfunction, peyronie's disease, hormone health and substance use disorders. The company's operating segment includes Prescription Medications and Medical Devices. It generates maximum revenue from the Medical Devices segment. The Prescription Medications segment consists primarily of operations related to Stendra, which is sold generally in the United States, and H100 for the treatment of Peyronie's disease.
Executives
Wayne Remell Walker director 1515 MARKET STREET, SUITE 1720, PHILADELPHIA PA 19103
Greg Bradley director 200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726
John D Shulman director, 10 percent owner
Jcp Iii Sm Aiv, L.p. 10 percent owner 5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Juggernaut Partners Iii Gp, L.p. 10 percent owner 5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Juggernaut Partners Iii Gp, Ltd. 10 percent owner 5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Metp Holdings Llc 10 percent owner 5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Joshua Silverman director IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Bruce Bernstein director 780 THIRD AVENUE, 12TH FLOOR, NEW YORK NY 10017
Keith Lavan officer: Chief Financial Officer 200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726
Fady Boctor officer: Pres. & Chief Comm. Officer 200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726
Andrew Gesek officer: President, Timm Medical 200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726
Metuchen Therapeutics, Llc 10 percent owner 5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Mitchell Arnold officer: Prin. Acct. Off/Prin. Fin. Off 200 ROUTE 9 NORTH, SUITE 500, MANALAPAN NJ 07726